the aid library

LIST OPTIONS

Filter

1714

Sort by:

Direction:

Download (1401)

View PDF (1977)

Management Of Drugs at Health Centre Level

WHO (2004) C_WHO

Training Manual

Download (179)

View PDF (278)

HEARTS. Technical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols

World Health Organization WHO, et al. (2018) C_WHO

In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood choles... more

Download (148)

View PDF (202)

HEARTS. Technical package for cardiovascular disease management in primary health care. Team-based care

World Health Organization WHO, et al. (2018) C_WHO

Many low-resource settings have a shortage of physicians and health workers. (1) In order to provide patient-centred continuous care more effectively, primary care systems can include team-based care strategies in their clinic workflows and protocols. Team-based care uses multidisciplinary teams (wh... more

Download (936)

View PDF (3415)

Needs Assessment & Evaluation form for essential emergency equipment in the emergency room

World Health Organization (2003)

Download (504)

View PDF (1035)

Nepal: National Drug Policy 1995

Ministry of Health, Department of Drug Administration (1995) C1

Download (361)

View PDF (594)

Namibia: Medicines and Related Substances Control Act

Government Gazette of the Republic of Namibia (2003) C2

GOVERNMENT NOTICE | No. 192 Promulgation of Medicines and Related Substances Control Act, 2003 (Act No. 13 of 2003), of the Parliament

Download (588)

View PDF (1560)

Uganda: THE NATIONAL DRUG POLICY AND AUTHORITY ACT

(1993) C2

CHAPTER 206 | An Act to establish a national drug policy and a national drug authority to ensure the availability, at all times, of essential, efficacious and cost-effective drugs to the entire population of Uganda, as a means of providing satisfactory health care and safeguarding the appropriate us... more

Download (1531)

View PDF (1667)

Anthropometric Indicators Measurement Guide 2003

Bruce Cogill Food and Nutrition Technical Assistance Project (2003) C2

Download (767)

View PDF (1082)

Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents

Lawrence Flick Memorial Tuberculosis Clinic, Philadelphia Tuberculosis Control Program (1998) C2

Download (17)

View PDF (16)

An overview of heart failure in low- and middle-income countries

Agbor, V.N.; Ntusi, N.A.B.; Noubiap, J.J. Cardiovascular Diagnosis and Therapy (2020) CC

Heart failure (HF) is a global public health concern with disproportionate socioeconomic, morbidity and mortality burden on low- and middle-income countries (LMICs). This review summarises contemporary data on the demographic and clinical characteristics, aetiologies, treatment, economic burden and ... more

Download (18)

View PDF (109)

Policy Snapshot: Cholesterol Control and Management in Brazil

World Heart Federation (2015) CC

Worldwide, there are about 17 million deaths due to cardiovascular disease (CVD) each year and at least two or three times as many non-fatal events. Raised cholesterol greatly increases the risks of stroke and heart disease, causing a large health burden across the world. The World Health Organizat... more

Download (22)

View PDF (24)

World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update

Freedman, B.; Hindricks, G.; Banerjee, A. Global Heart (2021) CC

The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death... more

Download (21)

View PDF (23)

MEPs Mobilising for Diabetes Blueprint for Action on Diabetes in the European Union by 2030

MEPs Mobilising for Diabetes (2021) CC2

Since the discovery of insulin nearly 100 years ago, advances in diabetes treatments and therapies have transformed the lives of people with diabetes (PwD), notably reducing the daily burden of its management. Newer technologies, including those driven by artificial intelligence, have the potentia... more

Download (28)

View PDF (17)

The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study

Khuluza, F.; Haefele-Abah, C. PLoS ONE (2019) CC

The Malawian government recently introduced cost-covering consultation fees for self-referral patients in tertiary public hospitals. Previously, patients received medicines free of charge in government-owned health facilities, but must pay elsewhere. Before the government implements a payment policy... more

Download (19)

View PDF (89)

Global action plan for the prevention and control of noncommunicable diseases 2013-2020 WHO

World Health Organization (WHO) World Health Organization (WHO) (2013) C_WHO

The Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020 by the World Health Organization (WHO) outlines a comprehensive strategy to address the global rise in noncommunicable diseases (NCDs), including cardiovascular diseases, cancer, chronic respiratory diseases,... more

Download (17)

View PDF (24)

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

Download (14)

View PDF (14)

National strategic Plan for the Prevention and Control of Non-Communicable diseases 2020-2025; South Africa National NCD Strategic Plan

World Health Organization WHO (2020) C_WHO

Non-Communicable Diseases (NCDs), including mental disorders, currently pose one of the biggest threats to health and development globally, particularly in low and middle income countries2. It is predicted that unless proven interventions are rapidly implemented in countries, in the short to medium ... more

Download (16)

View PDF (23)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Download (17)

View PDF (153)

Global tuberculosis report 2024

World Health Organisation (WHO) (2024) C_WHO

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

Download (6)

View PDF (5)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more